OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Clinical Oncology is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)

Article	Citations
Tasadenoturev active in DIPG	1155
A new standard of care for advanced-stage urothelial carcinoma	801
From little subclones grow mighty oaks	788
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	766
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	717
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	672
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	665
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	659
Novel ICI–TKI combination improves HCC outcomes	575
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	571
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	569
Ecological management of the microbiota in patients with cancer	548
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care	537
Hodgkin lymphoma: great progress with room for improvement	479
The emerging roles of circRNAs in cancer and oncology	478
Gut microbiota in colorectal cancer development and therapy	476
Current understanding and management of CAR T cell-associated toxicities	413
From the ESMO Congress 2021	390
From ESMO 2022	390
Mortality is similar with active monitoring	376
Contrasting results with second-line CAR T cells in large B cell lymphoma	363
Ponatinib superior to imatinib in Ph+ ALL	339
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	335
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	331
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	331

Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?	321
Sacituzumab tirumotecan improves OS in mTNBC	314
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	301
Predicting cancer outcomes with radiomics and artificial intelligence in radiology	293
Harnessing cytokines and chemokines for cancer therapy	280
Humanized mouse models for immuno-oncology research	258
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	242
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	237
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	231
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	230
Craniospinal irradiation improves leptomeningeal metastasis control	229
Survival benefit with second-line combination in endometrial cancer	217
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	214
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	212
Harnessing big data to characterize immune-related adverse events	211
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	210
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	210
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	208
Biomarkers for immunotherapy of hepatocellular carcinoma	204
Spatial landscapes of cancers: insights and opportunities	202
Improving outcomes in patients with oesophageal cancer	201
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	189
New CAPSTONE of SCLC therapy?	177
SHINE a light: frontline ibrutinib for MCL	172
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	170
Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions	170
Women with clinically node negative breast cancer can safely avoid axillary surgery	165
Aumolertinib is effective in NSCLC	164
Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond	164
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	156
From ESMO 2023: advances in lung cancer	149
DREAMseq of therapy for BRAF-mutant melanoma	148
Prospective comparisons support the use of navigational bronchoscopy	147
Mitigating acute chemotherapy-associated adverse events in patients with cancer	143
Targeting chromosomal instability in patients with cancer	142
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	141
Long-term outcomes following CAR T cell therapy: what we know so far	140
Circulating tumour DNA — looking beyond the blood	140
Benefit with ramucirumab in mesothelioma	130
Response to neoadjuvant endocrine therapy complements recurrence score	126
Multiomics STEP up in correlative analysis of response to CAR T cells	125
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	123
From the ESMO Congress 2023	117
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	113
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	108
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	108
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	103
HAIC-FO improves outcomes in HCC	98
Newly approved cancer drugs in China — innovation and clinical benefit	97
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	93

Claudin 18.2 as a novel therapeutic target	91
Lung cancer in patients who have never smoked — an emerging disease	89
Clinical implications of T cell exhaustion for cancer immunotherapy	88
Enhancing immunotherapy with tumour-responsive nanomaterials	88
Combining CAR T cells effective in RRMM	87
Targeted biopsy reduces detection of clinically insignificant cancer	87
Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	86
T-DXd effective as second-line therapy in G/GEJ cancers	83
Less-frequent surveillance is noninferior to annual mammography	80
Second-line tarlatamab improves OS in SCLC	80
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	79
Barriers in access to oncology drugs — a global crisis	76
Translating biological insights into improved management of endometrial cancer	73
Two decades of advances in clinical oncology — lessons learned and future directions	72
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	68
BrECADD raises the bar in classical Hodgkin lymphoma	67
Nirogacestat effective in desmoid tumours	66
HSCT prolongs remission of high-risk CTCLs	66
Promise with co-administration of CAR T cells	64
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	63
GPRC5D-CAR T cells active in MM	62
Promising OS with oncolytic virotherapy	60
Efficacy of TILs confirmed	60
Thermal ablation is safer than resection of colorectal liver lesions	59
Uncovering adagrasib resistance	56
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	54
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	54
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	54
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	52
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	51
The current state of the art and future trends in RAS-targeted cancer therapies	50
Exploiting bacteria for cancer immunotherapy	50
Neoadjuvant pembrolizumab improves outcomes	49
Repotrectinib effective in ROS1-fusion-positive NSCLC	49
MSI-H/dMMR mCRC: ICIs in the first line?	47
177Lu–PSMA-PET extends survival	46
Pembrolizumab tunes up chemotherapy in cervical cancer	45
Belzutifan is active in VHL-related cancers	42
LAG3 inhibition improves outcomes	38
KN046 shows tolerability and activity in TNBC	36
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	36
Problematic crossovers in cancer drug trials	35
The emerging roles of γδ T cells in cancer immunotherapy	35
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	35
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	34
Integrated MRI-guided radiotherapy — opportunities and challenges	34
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	32
CAR T cells induce durable remission of neuroblastoma	32
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	31
National value-based pricing negotiation for oncology drugs — lessons from China	27
Author Correction: EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment	27
Axicabtagene effective in indolent NHL	27
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	26
GPRC5D as a novel immunotherapeutic target in multiple myeloma	26
Therapeutic targeting of the hypoxic tumour microenvironment	25